^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Marginal Zone Lymphoma
    Drug:Calquence (acalabrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    01/25/2023
    Excerpt:
    Marginal Zone Lymphomas….Second-Line and Subsequent Therapy….Preferred regimens, BTK inhibitors...Acalabrutinib